Multivariate analysis identified EZH2 expression, age, T stage, lymph node metastasis, and tumor recurrence to be significantly correlated with prognosis in patients with LUAD (log-rank test, P = 0.048, 0.031, 0.026, < 0.01, and < 0.01, respectively), whereas only tumor recurrence was identified to be significantly correlated with prognosis in patients with LUSC (log-rank test, P < 0.01). This evidence concerns the gene EZH2 and metastatic malignant neoplasm in the lymph nodes.